Medical News

RSS

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Over a decade ago, Canadian patients diagnosed with chronic myeloid leukemia (CML), celebrated when PrGleevec (imatinib mesylate) was approved in Canada.

27 Jun 2011

Spectranetics initiates enrollment in EXCITE clinical trial against femoropopliteal IRS

Spectranetics Corporation today announces the first patient enrollment in the EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) clinical trial.

27 Jun 2011

First Edition: June 27, 2011

Today's headlines include reports about the status of ongoing deficit negotiations and details about a "stealth" survey on access to doctors.

27 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

BD receives CEO Cancer Gold Standard accreditation

BD has received CEO Cancer Gold Standard accreditation, recognizing the company's commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment for its own employees and their covered family members.

From BD (Becton, Dickinson and Company) 27 Jun 2011

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by ERYTECH Pharma.

27 Jun 2011

Derma Sciences announces $29 million financing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced it has closed its previously announced private placement.

27 Jun 2011

Ivantis receives $17 MM NEA, Delphi Ventures funds to expand Hydrus device clinical activities

Ivantis announced today at the World Glaucoma Congress in Paris that it has received $17 MM in funding from New Enterprise Associates (NEA) and Delphi Ventures.

27 Jun 2011

FDA accepts for filing Columbia's PROCHIEVE progesterone gel NDA

Columbia Laboratories, Inc. and Watson Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Columbia's New Drug Application (NDA) for PROCHIEVE (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy.

27 Jun 2011

STAAR Surgical completes first procedures to implant Visian ICL V4c design

STAAR Surgical Company, the leading developer, manufacturer and marketer of minimally invasive refractive lenses that go inside the eye, today announced the completion of the first procedures to implant its recently CE Mark-approved Visian Implantable Collamer Lens V4c design.

27 Jun 2011

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Dr Seizaburo Kashiwagi presented the preliminary data from an influenza Phase III prophylaxis study conducted during the 2009/2010 pandemic flu season in Japan.

27 Jun 2011

Study aims to find out whether blood screening can diagnose early breast cancer

A study spearheaded by the University of Leicester aims to find out whether a blood test can detect cancer, earlier than current methods, in women with a strong family history of breast cancer.

27 Jun 2011

Positive results from Stealth's Bendavia Phase I renal impairment study

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia.

27 Jun 2011

FDA issues Complete Response Letter for Pfizer's REMOXY NDA

DURECT Corporation today reported that Pfizer Inc. has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY, a controlled-release form of oxycodone designed to discourage common methods of tampering.

27 Jun 2011

New guide indicates when and how genetic testing is useful for inherited cardiac conditions

While genetic inheritance is known to play a role in the multifactorial development of most diseases of the heart, there are also a number of clearly diagnosed cardiac conditions which owe their development to quite specific genetic abnormalities. When these genetic disorders affect the integrity of the heart's muscle they are known as a "cardiomyopathy"; when the disorder affects the heart's "excitability", it is known as a "channelopathy".

27 Jun 2011

Study finds increase in life expectancy for people with type 1 diabetes

The life expectancy of people diagnosed with type 1 diabetes dramatically increased during the course of a 30-year, long-term prospective study, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 71st Scientific Sessions of the American Diabetes Association.

27 Jun 2011

SOGC launches first Facebook game about healthy sexuality for Canadians

Today, the Society of Obstetricians and Gynaecologists of Canada is launching its first Facebook game - Sex Quest - to help Canadians learn about healthy sexuality, contraception and STIs.

27 Jun 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.

27 Jun 2011

Former U.S. Surgeon General calls for intensive effort to promote child health

David Satcher, MD, PhD, former U.S. Surgeon General, describes childhood obesity as "one of the greatest threats to child and adult health that we are facing today," calling for an intensive effort to promote child health, in an editorial in the June issue of Childhood Obesity, a peer-reviewed journal published by Mary Ann Liebert, Inc. The editorial is available online.

27 Jun 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011